PolyPid Agrees With ADVANZ PHARMA To Terminate Their 2022 Exclusive License, Distribution And Supply Agreement For D-PLEX₁₀₀ In Europe

Benzinga Newsdesk www.benzinga.com Neutral 93.2%

Neg 0% Neu 93.2% Pos 0%

As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.

Comments

No comments yet. Be the first!